Sabatine et al developed a risk score for patients with unstable angina pectoris. This can help identify patients who have a survival benefit associated with therapy with glycoprotein IIb/IIIa inhibitor therapy. The authors are from Massachusetts General Hospital, Montreal Heart Institute and Merck Research Laboratories.